Table 1 Characteristics of 39 OCAC studies and 39,398 participants of European ancestry included in the Mendelian randomisation analysis

From: Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study

Study acronyma

Country

Diagnosis (years)

Median (range) age at diagnosis/interview

Invasive cases (N)

Borderline cases (N)

All cases (N)b

Controls (N)

Mean (SD) height (cm)c

AUS

Australia

2002–2006

58 (19–80)

859

1

860

977

163 (6.9)

BAV

Germany

2002–2008

58 (24–83)

96

5

102

143

164 (5.8)

BEL

Belgium

2007–2010

46 (19–87)

275

0

275

1347

DOV

USA

2002–2009

57 (35–74)

904

327

1231

1487

166 (6.5)

GER

Germany

1993–1998

57 (21–75)

189

24

213

413

163 (6.0)

GRR

USA

1981–2012

48 (21–83)

125

0

125

0

HAW

USA

1993–2008

56 (27–87)

60

20

80

157

163 (6.6)

HJO

Germany

2007–2011

54 (18–88)

261

13

290

273

HMO

Belarus

2006–2011

45 (22–76)

142

0

143

138

HOC

Finland

1975–1999

46 (18–86)

210

8

239

447

HOP

USA

2003–2009

58 (25–94)

567

71

723

1464

163 (6.8)

HSK

Germany

2000–2007

58 (18–81)

147

9

156

0

165 (5.6)

LAX

USA

1989–2008

58 (31–88)

278

0

278

0

MAL

Denmark

1994–1999

57 (31–80)

440

138

578

828

166 (6.1)

MAY

USA

2000–2010

61 (20–93)

699

79

778

743

165 (6.3)

MCC

Australia

1990–2008

65 (45–79)

66

0

66

66

159 (7.0)

MDA

USA

1997–2009

62 (23–88)

375

0

375

384

MSK

USA

1997–2010

57 (18–89)

450

0

450

593

NCO

USA

1999–2008

57 (20–75)

722

171

896

792

163 (6.4)

NEC

USA

1992–2003

52 (21–78)

654

232

904

1009

163 (6.7)

NJO

USA

2002–2009

60 (25–88)

169

0

169

181

163 (6.9)

NOR

Norway

2001–2010

51 (18–86)

236

12

248

371

NTH

Netherlands

1997–2008

55 (18–83)

292

3

295

323

167 (6.0)

ORE

USA

2007–2011

58 (22–86)

55

9

65

0

OVA

Canada

2002–2009

58 (19–80)

640

161

801

748

POC

Poland

1998–2008

55 (23–82)

423

0

423

417

POL

Poland

2000–2004

56 (24–74)

236

0

236

223

162 (5.6)

PVD

Denmark

2004–2009

63 (30–88)

168

0

168

0

165 (6.5)

RMH

UK

1993–1996

52 (26–73)

148

7

155

0

SEA

UK

1998–2011

57 (19–78)

1447

76

1530

6004

162 (6.3)

SOC

UK

1993–1998

62 (22–92)

268

20

288

0

SRO

UK

1999–2001

59 (34–84)

158

0

158

0

STA

USA

1997–2002

50 (20–64)

251

10

261

313

165 (6.7)

TOR

Canada

1995–2007

58 (26–85)

603

0

605

440

163 (7.1)

UCI

USA

1993–2005

56 (18–86)

277

141

418

367

165 (6.6)

UKO

UK

2006–2010

63 (19–89)

718

0

718

1104

162 (6.7)

UKR

UK

1991–2009

54 (24–77)

47

0

47

0

USC

USA

1992–2010

57 (22–82)

693

152

845

1047

165 (6.8)

WOC

Poland

1997–2010

44 (20–81)

201

2

203

204

  1. All participants were of >90% European ancestry according to genetic markers of ancestry.
  2. aOCAC is an international collaboration of largely case–control studies. See Supplementary Table 1 for study names and references. To maximise power, nine case-only studies were grouped for analysis with case–control studies from the same region: HSK combined with GER; GRR with HOP; PVD with MAL; RMH, SOC, SRO, UKR with SEA and UKO (‘UK group’); ORE with DOV; LAX with UCI.
  3. bCases had primary ovarian (n = 15,636), fallopian tube (n = 180) or peritoneal (n = 552) cancer or ovarian/tubal/peritoneal tumours of undetermined site (n = 27).
  4. cUsual adult height. Height is summarised for 22 studies (20 case–control studies) where >50% participants had data available (AUS, BAV, DOV, GER, HAW, HOP, HSK, MAL, MAY, MCC, NCO, NEC, NJO, NTH, POL, PVD, SEA, STA, TOR, UCI, UKO, USC). Sixteen of these 22 studies were also used in conventional height analyses, as they provided data on potential confounders (age, parity, use of oral contraceptives, education, and age at menarche) for >50% of participants (AUS, DOV, GER, HAW, HOP, MAL, NCO, NEC, NJO, NTH, POL, STA, TOR, UCI, UKO, USC).
  5. OCAC Ovarian Cancer Association Consortium, SD standard deviation